You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

shr-1701

Showing 1 - 12 of 12
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • SHR2554+ SHR1701
  • SHR-1701
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

NSCLC, Stage III Trial (SHR-1701)

Not yet recruiting
  • NSCLC, Stage III
  • SHR-1701
  • (no location specified)
Dec 14, 2021

Nasopharyngeal Carcinoma Trial in Guangzhou (SHR-1701, Gemcitabine, Cisplatin)

Active, not recruiting
  • Nasopharyngeal Carcinoma
  • SHR-1701
  • +3 more
  • Guangzhou, Guangdong, China
    Cancer Hospital of Guangzhou Sun Yat-sen University
Dec 19, 2021

Melanoma Trial in Shanghai (SHR-1701, Temozolomide)

Not yet recruiting
  • Melanoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 1, 2021

Solid Tumor Trial in China (SHR-1701)

Active, not recruiting
  • Solid Tumor
  • SHR-1701
  • Hefei, Anhui, China
  • +15 more
Nov 6, 2022

Squamous Cell Carcinoma of Head and Neck Trial in Beijing (SHR-1701)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • SHR-1701
  • Beijing, China
    Tumor Hospital of the Chinese Academy of Medical Sciences
Oct 28, 2021

Pancreatic Cancer Trial in Beijing, Shanghai (SHR-1701)

Unknown status
  • Pancreatic Cancer
  • SHR-1701
  • Beijing, China
  • +1 more
Sep 26, 2021

Nasopharyngeal Carcinoma Trial in Guangzhou (SHR-1701, Famitinib)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Hospital of Guangzhou Sun Yat-sen University
Aug 23, 2021

Solid Tumor Trial in China (SHR-1701, Famitinib)

Recruiting
  • Solid Tumor
  • Hefei, Anhui, China
  • +15 more
Jan 11, 2022

Lung Cancer Trial (SHR-1701; Famitinib, SHR-1701)

Not yet recruiting
  • Lung Cancer
  • SHR-1701； Famitinib
  • SHR-1701
  • (no location specified)
May 7, 2021

Non-Small-Cell Lung Cancer Trial (SHR-1701,Famitinib, SHR-1701)

Not yet recruiting
  • Non-Small-Cell Lung Cancer
  • (no location specified)
Jan 5, 2021

Non-Small-Cell Lung Cancer Trial (SHR-1701+Paclitaxel+carboplatin, SHR-1701)

Not yet recruiting
  • Non-Small-Cell Lung Cancer
  • (no location specified)
Oct 6, 2020